CTRI/2021/08/035384CompletedPhase 2
A randomized, double-blind, placebo controlled, proofof concept study assessing the efficacy and safety ofthe RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus - CLEan
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 5
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent
- •Participants with cutaneous lupus erythematosus either in the form of discoid/chronic cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus for at least 3 months before Screening.
- •Participants with histologically confirmed and documented diagnosis within one year prior to Screening or during Screening period prior to randomization.
- •Active cutaneous lupus erythematosus skin lesions and a CLASI-A =10 both at Screening and Baseline.
- •Participant who is candidate for systemic treatment per Investigator’s judgement.
- •ll Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •a) Male participants
- •Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 5 days after the last dose of IMP, corresponding to time needed to eliminate study intervention(s) (eg, 5 terminal half-lives)
- •Refrain from donating sperm
- •PLUS, either:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
- •Must agree to use contraception/barrier as detailed below:
- •A male condom and an additional highly effective contraceptive method as described in Appendix 4 Contraceptive and barrier guidance (Section 10.4) when
- •having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.
- •b) Female participants
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies
- •Is a woman of non-childbearing potential (WONCBP) as defined in Appendix 4 Contraceptive and barrier guidance (Section 10.4).
- •Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, as described in
- •Appendix 4 Contraceptive and barrier guidance (Section 10.4) during the study intervention period and for at least 2 days, corresponding to the time needed to eliminate any study intervention(s) (eg, 5 terminal half-lives) plus 30 days (a menstrual cycle) after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.
- •A WOCBP must have a negative highly sensitive pregnancy test (urine and/or serum as required by local regulations) at Screening and Baseline visits before the first administration of study intervention.
- •Pregnancy testing.
- •If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- •Local regulations regarding contraception for male and female participants
- •Capable of giving signed informed consent. In countries where legal age of majority is above 18 years, a specific ICF must also be signed by the participant’s legally authorized representative.
Exclusion Criteria
- •Suspected or proven drug induced lupus erythematosus, including patients with positive antihistone autoantibody tests.
- •Diagnosed with certain subtypes of CCLE (such as Lupus erythematosus tumidus, Chilblain, lupus panniculitis, lichenoid cutaneous lupus/lichen planus overlap syndrome).
- •Autoimmune disease(s) other than systemic lupus erythematosus (eg, systemic sclerosis, myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, multiple sclerosis, Behcet’s disease etc).
- •Active skin diseases that may interfere with the study or study assessments (eg, Psoriasis).
- •History of any malignancy except history of adequately treated basal cell carcinoma or in situ cervical carcinoma.
- •History of HIV infection or positive HIV serology at screening.
- •History of recurrent or recent serious infection (eg pneumonia, septicemia) within 4 weeks of screening, infection requiring hospitalization or intravenous antibiotics, antivirals or antifungals within 4 weeks of screening or chronic bacterial infections deemed unacceptable, as per Investigator’s judgement.
- •Surgery within 4 weeks prior to the screening visit or with planned surgery during the study.
- •Positive COVID-19 screening test, suspected of COVID-19 infection or known exposure to COVID-19 during the screening period.
- •Concomitant treatment with topical immunosuppressants beyond a stable regimen of low to medium potency topical corticosteroids and/or topical calcineurin inhibitors during the study and two weeks before baseline visit.
- •Systemic corticosteroids treatment <4 weeks before baseline visit.
- •Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study.
- •Participation in another clinical study 60 days before baseline visit.
- •Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
- •Any country-related specific regulation that would prevent the participant from entering the study.
- •Individuals with established dependency on drugs or alcohol, per the judgement of the investigator.
- •Any specific situation during study implementation/course that may rise ethics considerations.
- •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
Investigators
Similar Trials
Active, not recruiting
Phase 1
Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosusCutaneous Lupus ErythematosusEUCTR2020-004703-14-HUSanofi-Aventis Recherche & Développement135
Active, not recruiting
Phase 1
Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosusMedDRA version: 21.1Level: PTClassification code 10056509Term: Cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersCutaneous Lupus ErythematosusEUCTR2020-004703-14-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT135
Active, not recruiting
Phase 1
Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosusMedDRA version: 21.1Level: PTClassification code 10056509Term: Cutaneous lupus erythematosusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersCutaneous Lupus ErythematosusEUCTR2020-004703-14-PLSanofi-Aventis Recherche & Développement135
Unknown
Phase 3
A clinical trial to study the effect of cough mixture syrup of levosalbutamol, ambroxol and guaiphenesin in the treatment of patients suffering from productive cough associated with acute bronchitis.CTRI/2012/03/002477Glenmark Pharmaceuticals Ltd260
Active, not recruiting
Phase 1
Study of a new therapeutic agent used to treat portopulmonary hypertensioPortopulmonary hypertensionMedDRA version: 20.0Level: PTClassification code 10067281Term: Portopulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004624-21-CZACTELION Pharmaceuticals Ltd.84